文献速递腹部泌尿生殖CT

直肠癌CT淋巴结Node-RADS评估及临床病理相关性

CT-based Node-RADS for standardized evaluation of lymph node metastasis in rectal cancer and its clinicopathological correlates
RSS 订阅 · European Journal of Radiology · 2026-10-15

本研究为单中心回顾性研究,纳入459例未经治疗的直肠癌患者,由两名阅片者依据CT Node-RADS 1.0对淋巴结转移风险进行评分。结果显示Node-RADS≥3时敏感度较高,≥4时特异度较高,两名阅片者AUC分别为0.831和0.806。Node-RADS评分与病理T分期、N分期及淋巴血管侵犯相关,阅片者间一致性为substantial。

要点

  • Node-RADS≥3适合筛查淋巴结转移,敏感度可达87.36%(Reader 1)
  • Node-RADS≥4用于提高诊断特异度,特异度达78.95%(Reader 1)
  • Node-RADS评分越高,病理T分期、N分期及淋巴血管侵犯风险越高

核心结论

  • CT-based Node-RADS在未经治疗的直肠癌患者中具有稳定且令人满意的淋巴结转移诊断效能。
  • Node-RADS评分与病理T分期、N分期及淋巴血管侵犯显著相关。

研究设计与样本

  • 由两名阅片者采用Node-RADS 1.0对淋巴结进行1至5分评分,以术后病理淋巴结状态为参考标准。

关键影像表现/征象

  • Node-RADS评分高低反映CT上淋巴结转移风险分层,但原文未描述具体CT征象与评分的形态学对应细节。

诊断标准与关键数值

  • Node-RADS≥3:Reader 1敏感度87.36%,特异度58.25%,Youden指数0.46;Reader 2敏感度89.08%,特异度54.04%,Youden指数0.43。
  • Node-RADS≥4:Reader 1敏感度74.14%,特异度78.95%,Youden指数0.53;Reader 2敏感度72.99%,特异度75.44%,Youden指数0.48。
  • Node-RADS评分AUC:Reader 1为0.831(95%CI:0.793-0.864),Reader 2为0.806(95%CI:0.767-0.841)。
  • Node-RADS评分阅片者间一致性为substantial,加权kappa值为0.650。

临床应用与阅片要点

  • 在日常阅片中可先采用Node-RADS≥3作为敏感筛查阈值以识别潜在淋巴结转移患者。
  • 需要更高特异度以减少假阳性时,可考虑采用Node-RADS≥4作为判读阈值。
  • Node-RADS评分升高时应警惕更高病理T分期、N分期及淋巴血管侵犯的可能性。

局限性

  • 本研究为单中心回顾性设计。
英文原文(摘要)· 点击展开

BACKGROUND: Lymph node metastasis identification has important clinical implications for treatment decision-making in rectal cancer (RC). To evaluate the diagnostic performance of the CT-based Node Reporting and Data System 1.0 (Node-RADS) for lymph node metastasis risk in treatment-naive RC patients, and to investigate the correlation between the Node-RADS score and clinicopathological factors.

METHODS: A single-center retrospective study was performed to RC patients (Aug 2020-Dec 2025) who underwent radical resection surgery and preoperative contrast-enhanced CT examination. Lymph node status was assessed using Node-RADS score ranging from 1 to 5. Sensitivity, specificity, and Youden's index were calculated for different Node-RADS cut-off values. The overall diagnostic performance was evaluated using receiver operating characteristic curves and the area under the curve (AUC). The associations between Node-RADS score and clinicopathological parameters were analyzed.

RESULTS: A total of 459 RC patients were evaluated, including 174 pN + and 285 pN-. Node-RADS scores ≥ 3 and ≥ 4 have the satisfactory diagnostic performance, with sensitivity/ specificity/Youden's index of 87.36 %/58.25 %/0.46 for Node-RADS scores ≥ 3 by Reader 1, 89.08 %/54.04 %/0.43 for Node-RADS scores ≥ 3 by Reader 2, 74.14 %/78.95 %/0.53 for Node-RADS scores ≥ 4 by Reader 1, and 72.99 %/75.44 %/0.48 for Node-RADS scores ≥ 4 by Reader 2, respectively. The AUC of Node-RADS scores were 0.831(95 %CI:0.793-0.864) and 0.806(95 %CI:0.767-0.841) by Reader 1 and Reader 2, respectively. Node-RADS score correlated with pathological T stage, N stage, and lymphovascular invasion. The inter-reader agreement for Node-RADS score were substantial, with weighted kappa values of 0.650.

CONCLUSIONS: The CT-based Node-RADS demonstrates stability and satisfactory diagnostic performance for identifying patients with lymph node metastasis in treatment-naive RC.

来源:European Journal of Radiology,查看原文。版权归原作者所有。

引用

  1. European Journal of Radiology:CT-based Node-RADS for standardized evaluation of lymph node metastasis in rectal cancer and its clinicopathological correlates
  2. Xiao, Jiang, Chen, et al. CT-based Node-RADS for standardized evaluation of lymph node metastasis in rectal cancer and its clinicopathological correlates. Eur J Radiol. 2026. PMID: 42896449. doi:10.1016/j.ejrad.2026.113306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。